"What makes biotech amenable to this type of investing is that at the end of the day you get a 'yes' or a 'no' answer on a drug," said Stifel Nicolaus senior analyst Brian Klein. "Those binary events allow you to make bets with large swings, so you can make a lot of money as an investor on either end of a stock."
Read More Top short seller makes an extreme bet
But even before a final decision is made, the biotech industry has regular sets of deadlines that are conducive for short sellers, whose bets in other industries could take years to pay off.
These regimented timetables offer investors "higher-than-average potential for stock-specific news," especially for the smaller pre-commercial stocks whose fortunes ride on a single product, said Chad Messer, Needham & Co.'s senior biotechnology analyst.
Read More Top biotech analyst calls out Janet Yellen's comments
Both Messer and Klein cover Geron, a California-based biotechnology company that ties for 12th on Markit's weekly list of most-shorted stocks. Ahead of Geron's earnings, about 13.9 percent of the company's shares outstanding are on loan, according to Markit.
Both analysts maintain a "hold" on the company. Earlier this year, Geron's only drug, imetelstat, received a Food and Drug Administration clinical hold for its trials to treat a rare type of blood cancer, but Messer and Klein both indicated that they expected the issue would blow over.
Read More Cramer's single stock solution for those baffled by biotech
This sort of news, and the lingering questions about imetelstat's efficacy compared to its toxicity, explain why bears are piling into the stock, they said.
Another heavily shorted biotechnology company announcing earnings this week is facing less defined fears about its future. PDL BioPharma ranks third on Markit's list with 22.6 percent of its shares outstanding on loan.
Rather than deadlines for clinical trials, the company is dealing with investor concern over the viability of its business model, said RBC Capital Markets analyst Adnan Butt. For the past few years, PDL BioPharma has operated as an owner of biotech patents and royalty assets, but the strategy has a "young history," Butt said.
Read More Taking the ice bucket challenge
Despite the short sellers identifying this strategy as a potential weakness, many investors are sticking with the stock—keeping it above $9 per share—because of its high dividend, said Kimberly Lee, senior biotech analyst for Janney Montgomery Scott. Both Lee and Butt have a "hold" rating on the stock.
Here's Markit's complete list of most shorted stocks with earnings announcements this week: